The New York Times on Drugs
| 12 Comments |

It is hardly surprising that The New York Times comes out with an anti-pharmaceutical screed on a regular basis. I usually just ignore them, but Thursday's article in Business Day was so slanted and amateurish that I couldn't pass up the opportunity to call them out.

The headline itself was the worst offender: "Brand-Name Drug Prices Rise Sharply, Report Says."

I'm guessing that they hoped that their readers would simply read the headline, mentally file away yet another pharmaceutical industry crime against humanity (soaking the consumer even more), and move on to the sports section to read about the Jets (arguably another crime against humanity).

Because if anyone had bothered to read the whole article, what is really going on is staring you straight in the face. But first, let's talk about some of the more disingenuous aspects of the report.

The first sentence reads "The price of brand-name prescription medicines is rising far faster than the inflation rate, while the price of generic drugs has plummeted, creating the largest gap so far between the two, according to a report published Wednesday by the pharmacy benefits manager Express Scripts."

The increase in branded drugs is 13 percent over the past year, while the price of generics has fallen by 22 percent. These numbers are both misleading and meaningless.

The obvious conclusion from the headline is: Those awful drug companies are making out like bandits, while the "little guys"--the generic companies-- are suffering. And the difference between the rate of inflation and brand name drug prices is bona fide proof of this. Sounds good, but in this case, the use of the inflation rate as a surrogate measure of pharmaceutical company "greediness" is not only utterly meaningless, but intentionally deceiving.

Buried in the middle of the article are two sentences which give the real reason for the price increases, and I have to give them some credit for at least mentioning it. The report cited the growth of specialty drugs, which treat diseases like cancer and multiple sclerosis, as a major reason for the increase in spending on branded drugs. Spending on specialty medicines increased nearly 23 percent during the first three quarters of 2012, compared with the same period in 2011.

New brand name drugs are nothing like they were 10 or 20 years ago. We are talking about a whole different animal, so drawing any conclusion from these data is impossible. You might as well use the price of pork bellies on the Chicago Mercantile Exchange. Here's why.

The well-known "patent cliff" and supposed "lack of innovation" have put pharmaceutical companies in bad shape. This has not only led to the ongoing deconstruction of US-based research, but also a radical shift in the type of research that is being done.

A major consequence of this trend is that pills are pretty much passé. Virtually the entire industry has rapidly re-focused on specialty drugs--very expensive and often individualized therapies (most are biologics) that are mostly new therapies for cancer and autoimmune disorders--the areas that people (and sometimes insurance companies) are willing to pay $100 thousand dollars per year for a new drug.

The Express Scripts report explains quite nicely what is really going on--almost all of the newly approved drugs since July 1 fall under the category of speciality drugs. And yes--they are very expensive.

This is why branded drugs are outpacing inflation (as if that has anything to do with anything)--not because we are seeing massive price hikes on older brand drugs.

The fact that this shift in drug research has led to the use of much more personalized, difficult to manufacture and expensive drugs is the real story. Blindly comparing meaningless inflation data to make a point is disingenuous and inaccurate. One would think that The Times would strive for higher standards than the junk they put out this week.

12 Comments

The author of this piece is a genius. I love him like a brother.

A surprising omission is the fact that for the past 30 years The New York Times has loudly trumpeted the use of harsher and ever more toxic drugs to "treat" HIV, the putative cause of AIDS. They never questioned the efficacy or propriety of such chemical interventions or the questionable trials that led to rapid FDA approvals.

For a superb overview as to why that occurred, see H. Gilbert Welsh, M.D. et al., "Over-Diagnosed: Making People Sick in the Pursuit of Health." [2011]

Charity begins at home, Dr. Bloom. Start with the book by Dr. Welsh and give us your assessment, without wisecracks if possible.

I'm not surprised that you would shun a book by three physicians that might challenge some of your conservative convictions.

That you make an irrelevant religious analogy suggests a not-so-subtle religious commitment on your part that borders on fundamentalism.

As I alluded to near the outset of the exchange, get help Josh so you can quit pretending to be a scientist.

As an unbiased third party, I would have to award the victory in the above debate to Dr. Bloom. His opponent, while obviously educated, seems weirdly delusional. If this was a kids' softball game, I'd invoke the mercy rule. Chuck is in over his head; stop the fight!

Note to Bill Michaels: Josh and I have cordially agreed to continue our correspondence via private emails.

Rather than a kids softball game, please know that I did offer to engage in an open public debate forum with a neutral moderator at the Manhattan Institute on the topic of the definition, causes, cures, and prevention of "AIDS cases" in Africa (ca. 1980-2012).

Were it to be held, you too could attend and judge the outcome for yourself....in person.

Chuck

BTW, I know there are many paradoxes in the hiv science, too many actually, that it would not surprise me to know that this bug is not the culprit at all

"When is the last time you read about anyone dying from complications from AIDS? It used to be commonplace."

http://www.pinknews.co.uk/2012/12/19/gay-bareback-porn-star-dies-of-hiv-related-complications/

Related Entries:


keep in touch     Follow Us on Twitter  Facebook  Facebook


Our Research

Rhetoric and Reality—The Obamacare Evaluation Project: Cost
by Paul Howard, Yevgeniy Feyman, March 2013


Warning: mysql_connect(): Unknown MySQL server host 'tmiweb52.vwh.net' (2) in /home/medicalp/public_html/incs/reports_home.php on line 17
Unknown MySQL server host 'tmiweb52.vwh.net' (2)
Archives

Blogroll

American Council on Science and Health
in the Pipeline
Drugwonks
Pharmalot
Reason – Peter Suderman
WSJ Health Blog
The Hill’s Healthwatch
Forbes ScienceBiz
The Apothecary
EyeOnFDA
KevinMD
Marginal Revolution
Megan McArdle
LifeSci VC
Critical Condition
EconLog
In Vivo Blog
PharmaGossip
Pharma Strategy Blog
Drug Discovery Opinion